Follow
Peter Auguste
Peter Auguste
Research Fellow in Health Economics
Verified email at warwick.ac.uk
Title
Cited by
Cited by
Year
Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness
AK Ewer, AT Furmston, LJ Middleton, JJ Deeks, JP Daniels, HM Pattison, ...
Health Technol Assess 16 (2), 1-184, 2012
1942012
Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and …
P Auguste, A Tsertsvadze, J Pink, R Court, N McCarthy, P Sutcliffe, ...
BMC infectious diseases 17, 1-13, 2017
1442017
Pulse oximetry as a screening test for congenital heart defects in newborn infants: a cost-effectiveness analysis
TE Roberts, PM Barton, PE Auguste, LJ Middleton, AT Furmston, AK Ewer
Archives of disease in childhood 97 (3), 221-226, 2012
1322012
Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic …
CL Althaus, KME Turner, CH Mercer, P Auguste, TE Roberts, G Bell, ...
Health technology assessment (Winchester, England) 18 (2), 1-viii, 2014
1292014
Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation
P Royle, H Mistry, P Auguste, D Shyangdan, K Freeman, N Lois, N Waugh
Health Technology Assessment 19 (51), 1-248, 2015
882015
Evaluating PET‐CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation
C Meads, C Davenport, S Małysiak, M Kowalska, A Zapalska, P Guest, ...
BJOG: An International Journal of Obstetrics & Gynaecology 121 (4), 398-407, 2014
572014
An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence
P Auguste, P Barton, C Hyde, TE Roberts
NIHR Health Technology Assessment programme: Executive Summaries, 2011
502011
Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high …
P Auguste, A Tsertsvadze, J Pink, F Seedat, T Gurung, K Freeman, ...
Health Technology Assessment (Winchester, England) 20 (38), 1-678, 2016
492016
Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective …
C Meads, P Auguste, C Davenport, S Małysiak, S Sundar, M Kowalska, ...
Health technology assessment (Winchester, England) 17 (12), 1, 2013
472013
Evaluating PET–CT in routine surveillance and follow‐up after treatment for cervical cancer: a cost‐effectiveness analysis
P Auguste, P Barton, C Meads, C Davenport, S Małysiak, M Kowalska, ...
BJOG: An International Journal of Obstetrics & Gynaecology 121 (4), 464-476, 2014
432014
Valuing the health states associated with Chlamydia trachomatis infections and their sequelae: a systematic review of economic evaluations and primary studies
LJ Jackson, P Auguste, N Low, TE Roberts
Value in Health 17 (1), 116-130, 2014
402014
Short-and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled …
X Armoiry, A Kan, GJ Melendez-Torres, R Court, P Sutcliffe, P Auguste, ...
Journal of Neurology 265, 999-1009, 2018
352018
Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
GJ Melendez-Torres, P Auguste, X Armoiry, H Maheswaran, J Madan, ...
Health Technology Assessment 21 (52), I-+, 2017
352017
Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent …
K Freeman, M Connock, P Auguste, S Taylor-Phillips, H Mistry, ...
Health Technology Assessment 20 (83), 1-288, 2016
332016
Court, R.; McCarthy, N.; Sutcliffe, P.; Clarke, A. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that …
P Auguste, A Tsertsvadze, J Pink
BMC Infect. Dis 17 (1), 200, 2017
292017
Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
M Connock, P Auguste, C Dussart, J Guyotat, X Armoiry
Journal of Neuro-Oncology 143, 605-611, 2019
282019
Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including …
GJ Melendez-Torres, X Armoiry, R Court, J Patterson, A Kan, P Auguste, ...
BMC neurology 18, 1-17, 2018
252018
How do pharmaceutical companies model survival of cancer patients? A review of NICE single technology appraisals in 2017
D Gallacher, P Auguste, M Connock
International journal of technology assessment in health care 35 (2), 160-167, 2019
192019
A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups
P Auguste, A Tsertsvadze, R Court, J Pink
Tuberculosis 99, 81-91, 2016
192016
Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?
H Mistry, P Auguste, N Lois, N Waugh
BMJ open ophthalmology 2 (1), e000021, 2017
172017
The system can't perform the operation now. Try again later.
Articles 1–20